These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

766 related items for PubMed ID: 18977445

  • 1. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products.
    Ressing ME, Horst D, Griffin BD, Tellam J, Zuo J, Khanna R, Rowe M, Wiertz EJ.
    Semin Cancer Biol; 2008 Dec; 18(6):397-408. PubMed ID: 18977445
    [Abstract] [Full Text] [Related]

  • 2. Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.
    Quinn LL, Zuo J, Abbott RJ, Shannon-Lowe C, Tierney RJ, Hislop AD, Rowe M.
    PLoS Pathog; 2014 Aug; 10(8):e1004322. PubMed ID: 25144360
    [Abstract] [Full Text] [Related]

  • 3. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
    Albanese M, Tagawa T, Bouvet M, Maliqi L, Lutter D, Hoser J, Hastreiter M, Hayes M, Sugden B, Martin L, Moosmann A, Hammerschmidt W.
    Proc Natl Acad Sci U S A; 2016 Oct 18; 113(42):E6467-E6475. PubMed ID: 27698133
    [Abstract] [Full Text] [Related]

  • 4. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
    Croft NP, Shannon-Lowe C, Bell AI, Horst D, Kremmer E, Ressing ME, Wiertz EJ, Middeldorp JM, Rowe M, Rickinson AB, Hislop AD.
    PLoS Pathog; 2009 Jun 18; 5(6):e1000490. PubMed ID: 19557156
    [Abstract] [Full Text] [Related]

  • 5. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma.
    Taylor GS, Haigh TA, Gudgeon NH, Phelps RJ, Lee SP, Steven NM, Rickinson AB.
    J Virol; 2004 Jan 18; 78(2):768-78. PubMed ID: 14694109
    [Abstract] [Full Text] [Related]

  • 6. Long-term carriers generate Epstein-Barr virus (EBV)-specific CD4(+) and CD8(+) polyfunctional T-cell responses which show immunodominance hierarchies of EBV proteins.
    Ning RJ, Xu XQ, Chan KH, Chiang AK.
    Immunology; 2011 Oct 18; 134(2):161-71. PubMed ID: 21896011
    [Abstract] [Full Text] [Related]

  • 7. Immune Evasion by Epstein-Barr Virus.
    Ressing ME, van Gent M, Gram AM, Hooykaas MJ, Piersma SJ, Wiertz EJ.
    Curr Top Microbiol Immunol; 2015 Oct 18; 391():355-81. PubMed ID: 26428381
    [Abstract] [Full Text] [Related]

  • 8. The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and elimination.
    Jochum S, Moosmann A, Lang S, Hammerschmidt W, Zeidler R.
    PLoS Pathog; 2012 Oct 18; 8(5):e1002704. PubMed ID: 22615564
    [Abstract] [Full Text] [Related]

  • 9. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
    Münz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, Kurilla MG, Zhang D, O'Donnell M, Steinman RM.
    J Exp Med; 2000 May 15; 191(10):1649-60. PubMed ID: 10811859
    [Abstract] [Full Text] [Related]

  • 10. T cells specific for different latent and lytic viral proteins efficiently control Epstein-Barr virus-transformed B cells.
    Nowakowska J, Stuehler C, Egli A, Battegay M, Rauser G, Bantug GR, Brander C, Hess C, Khanna N.
    Cytotherapy; 2015 Sep 15; 17(9):1280-91. PubMed ID: 26276009
    [Abstract] [Full Text] [Related]

  • 11. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
    Piriou E, Jansen CA, van Dort K, De Cuyper I, Nanlohy NM, Lange JM, van Oers MH, Miedema F, van Baarle D.
    J Immunol; 2005 Aug 01; 175(3):2010-7. PubMed ID: 16034146
    [Abstract] [Full Text] [Related]

  • 12. The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.
    Quinn LL, Williams LR, White C, Forrest C, Zuo J, Rowe M.
    J Virol; 2016 Jan 01; 90(1):356-67. PubMed ID: 26468525
    [Abstract] [Full Text] [Related]

  • 13. Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers.
    Daskalogianni C, Pyndiah S, Apcher S, Mazars A, Manoury B, Ammari N, Nylander K, Voisset C, Blondel M, Fåhraeus R.
    J Pathol; 2015 Jan 01; 235(2):334-41. PubMed ID: 25186125
    [Abstract] [Full Text] [Related]

  • 14. Novel method for detection of virus-specific CD41+ T cells indicates a decreased EBV-specific CD4+ T cell response in untreated HIV-infected subjects.
    Piriou ER, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D.
    Eur J Immunol; 2005 Mar 01; 35(3):796-805. PubMed ID: 15724243
    [Abstract] [Full Text] [Related]

  • 15. T cell detection of a B-cell tropic virus infection: newly-synthesised versus mature viral proteins as antigen sources for CD4 and CD8 epitope display.
    Mackay LK, Long HM, Brooks JM, Taylor GS, Leung CS, Chen A, Wang F, Rickinson AB.
    PLoS Pathog; 2009 Dec 01; 5(12):e1000699. PubMed ID: 20019813
    [Abstract] [Full Text] [Related]

  • 16. MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response.
    Long HM, Chagoury OL, Leese AM, Ryan GB, James E, Morton LT, Abbott RJ, Sabbah S, Kwok W, Rickinson AB.
    J Exp Med; 2013 May 06; 210(5):933-49. PubMed ID: 23569328
    [Abstract] [Full Text] [Related]

  • 17. Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy.
    Adhikary D, Behrends U, Boerschmann H, Pfünder A, Burdach S, Moosmann A, Witter K, Bornkamm GW, Mautner J.
    PLoS One; 2007 Jul 04; 2(7):e583. PubMed ID: 17611619
    [Abstract] [Full Text] [Related]

  • 18. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
    Lee SP, Brooks JM, Al-Jarrah H, Thomas WA, Haigh TA, Taylor GS, Humme S, Schepers A, Hammerschmidt W, Yates JL, Rickinson AB, Blake NW.
    J Exp Med; 2004 May 17; 199(10):1409-20. PubMed ID: 15148339
    [Abstract] [Full Text] [Related]

  • 19. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
    Mautner J, Bornkamm GW.
    Eur J Cell Biol; 2012 Jan 17; 91(1):31-5. PubMed ID: 21458882
    [Abstract] [Full Text] [Related]

  • 20. Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection.
    Ressing ME, Keating SE, van Leeuwen D, Koppers-Lalic D, Pappworth IY, Wiertz EJ, Rowe M.
    J Immunol; 2005 Jun 01; 174(11):6829-38. PubMed ID: 15905524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.